Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis |
| |
Authors: | Ishida Masaharu Sunamura Makoto Furukawa Toru Akada Masanori Fujimura Hiroko Shibuya Emiko Egawa Shinichi Unno Michiaki Horii Akira |
| |
Affiliation: | 1. Departments of Molecular Pathology, Tohoku University School of Medicine, 2-1Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan;Department of Gastroenterological Surgery, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku,Sendai 980-8574, Japan 2. Department of Gastroenterological Surgery, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku,Sendai 980-8574, Japan;Cancer Surgery Section, Hammersmith Hospital, Imperial College, Du Cane Road, London W12 ONN,United Kingdom 3. Departments of Molecular Pathology, Tohoku University School of Medicine, 2-1Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan 4. Department of Gastroenterological Surgery, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku,Sendai 980-8574, Japan |
| |
Abstract: | AIM: To evaluate the significance of BNIP3 in the pathogenesis of pancreatic cancer, we analyzed the relationship between the expression of BNIP3 and survival rate of the patients with pancreatic cancer, or chemosensitivities in pancreatic cancer cell lines, particularly for gemcitabine, the first-line anti-tumor drug for pancreatic cancer. METHODS: To compare the expression level of BNIP3 with the resistance to gemcitabine, eight pancreatic cancer cell lines were subjected to gemcitabine treatment and the quantitative real-time RT-PCR method was used to evaluate BNIP3 expression. Immunohistochemical analysis was also performed using 22 pancreatic cancer specimens to study relationship between BNIP3 expression and survival rate. RESULTS: Although no significantly positive association between BNIP3 mRNA level and gemcitabine chemosensitivity was observed, pancreatic cancer cell lines that were sensitive to gemcitabine treatment tended to show high levels of BNIP3 expression. The converse, an absence of BNIP3 expression, was not correlated with gemcitabine resistance. We further compared the BNIP3 expression profiles of resected primary pancreaticcancer specimens with the prognosis of the patients, and found a tendency of favorable prognosis and low BNIP3 expression. CONCLUSION: High levels of BNIP3 expression cannot be used as one of the predicting factors for gemcitabine chemosensitivity, and some yet to be known factors will have to fill the gap for the accurate prediction of pancreatic cancer chemosensitivity to gemcitabine. However, BNIP3 expression may have an impact on prediction of prognosis of patients with pancreatic cancer. |
| |
Keywords: | BNIP3 Chemosensitivity Gemcitabine Pancreatic cancer Prognosis |
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录! |
|